| Biomarker Panel for Classification of Renal Cell Carcinoma
miRNA SSNA in situ Hybridization System
Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct tumors, the most prevalent of which are clear cell renal cell carcinoma (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC). Accurate distinction between the RCC subtypes poses a challenge for pathologists, as they share a wide range of common features and has overlapping immunohistochemical profiles. Subtypes also have different survival outcomes and responses to therapy. Although surgical resection remains the gold standard treatment for RCC, long-term complications, morbidity and mortality of RCC are difficult to accurately predict. Also, the current approaches to chemotherapy and radiotherapy have only limited efficacy on RCC. Therefore, accurate classification of RCC is critical for clinical decision making. Accumulating evidence has reported microRNAs (miRNAs) as promising biomarkers for early cancer detection, accurate prognosis, as well as molecular targets for cancer treatment. Aberrant expression of miRNAs has been reported to be associated with progression of renal cancer. Evaluation of miRNA profiles in RCC holds promise for improving understanding of pathogenesis and therapeutic outcome.
Please click on below links to download Renal Cell Carcinoma Classification Biomarker Panel and Application Note.
BioGenex also has an extensive catalog of 235 unique miRNA probes